Dermatology
Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.
Armstrong AW, Jayade S, Rege S, Penton H, Patel V, Davidson D, Kalirai S, Wolin D, Boyle K, Seigel L. Evaluating prevalence and consequence of residual disease among patients with moderate to severe psoriasis in the United States. Poster presented at the 2023 EADV Congress; October 11, 2023. Berlin, Germany. Previously presented at the Maui Derm Hawaii 2023.
INTRODUCTION AND OBJECTIVES: To assess unmet needs in psoriasis (PsO), this study assessed the prevalence of and factors associated with residual disease in patients (pts) with moderate to severe PsO receiving apremilast, and compared clinical and humanistic burden in apremilast users with vs without residual disease.
Armstrong AW, Seigel L, Jayade S, Rege S, Penton H, Patel V, Davidson D, Kalirai S, Wolin D, Boyle K, Bhutani T. Assessing humanistic burden among patients with moderate to severe psoriasis in the United States. Poster presented at the 2023 EADV Congress; October 11, 2023. Berlin, Germany. Previously presented at the 2023 Annual Symposium Society of Detmatology Nurse Practitioners (SDNP).
INTRODUCTION & OBJECTIVES: Various treatments for psoriasis are available, yet evidence reveals substantial humanistic burden remains. This study assessed the humanistic burden among patients with moderate to severe psoriasis.
Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Trea. 2023 Dec;34(1):2215356. doi: 10.1080/09546634.2023.2215356.
Armstrong AW, Seigel L, Jayade S, Rege S, Penton H, Patel V, Davidson D, Kalirai S, Wolin D, Boyle K, Bhutani T. Assessing humanistic burden among patients with moderate to severe psoriasis in the United States. Poster presented at the 2023 Annual Symposium Society of Detmatology Nurse Practitioners (SDNP); April 10, 2023. Park City, UT. Previously presented at the Maui Derm Hawaii 2023.
BACKGROUND: Psoriasis is a chronic inflammatory condition that diminishes patients’ quality of life (QoL; Armstrong AW, et al. Adv Ther 2022).
OBJECTIVE: This study aimed to assess and compare the humanistic burden in patients with moderate to severe psoriasis.
Bego G, Tavi J, Wang Z, Kuznik A, Brignoli L, Mnif T, Wolowacz S, Jia X. Quality of life of caregivers of pediatric patients with atopic dermatitis: a quantitative assessment of utilities from EQ-5D. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2022 Jan; 25(1, Supplement):S101. doi: 10.1016/j.jval.2021.11.480
Sweeney C, Calingaert B, Holzmann R, Moeller C, Schomakers G, Sok A, Pisa F, Gilsenan A. Physician knowledge of safe use of cyproterone acetate monotherapies and meningioma. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):300. doi: 10.1002/pds.5687
Armstrong AW, Seigel L, Jayade S, Rege S, Penton H, Patel V, Davidson D, Kalirai S, Wolin D, Boyle K, Bhutani T. Assessing humanistic burden among patients with moderate to severe psoriasis in the United States. Poster presented at the Maui Derm Hawaii 2023; January 23, 2023. Maui, HI.
Abstract not available at this time.